论文部分内容阅读
目的:观察长春瑞滨联合顺铂(NP)对蒽环类和紫杉类耐药晚期乳腺癌的疗效。方法:选择78例葸环类和紫杉类治疗后失败的晚期乳腺癌患者接受NP方案化疗,评价疗效和不良反应。结果:78例患者CR、PR、SD、PD分别为6.4%、41.0%、34.6%、17.9%,总缓解率47.4%,肿瘤控制率为82.1%。绝经后患者疗效优于绝经前,仅软组织、淋巴结转移的患者优于内脏转移的患者,ER或PR阳性的患者优于ER、PR均阴性的患者(P<0.05)。结论:NP方案治疗蒽环类和紫杉类耐药的晚期乳腺癌疗效确切,患者可耐受,且疗效与患者的绝经状态、转移部位、激素受体情况有关。
Objective: To observe the effect of vinorelbine combined with cisplatin (NP) on anthracycline and taxane-resistant advanced breast cancer. Methods: A total of 78 patients with advanced breast cancer who failed in the treatment of acenaphthene and taxanes received NP regimen to evaluate the efficacy and adverse reactions. Results: The CR, PR, SD and PD of the 78 patients were 6.4%, 41.0%, 34.6% and 17.9% respectively, with a total response rate of 47.4% and a tumor control rate of 82.1%. The effect of postmenopausal patients was better than premenopausal, soft tissue, lymph node metastasis patients with visceral metastasis, ER or PR positive patients than ER, PR were negative patients (P <0.05). CONCLUSION: The NP regimen is effective in treating patients with advanced breast cancer who are resistant to anthracyclines and taxanes. The efficacy of the NP regimen is related to the menopausal status, metastatic sites and hormone receptors.